- Home
- ACTU vs IGA Comparison
ACTU vs IGA Comparison
Compare ACTU & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- IGA
- Stock Information
- Founded
- ACTU 2015
- IGA 2005
- Country
- ACTU United States
- IGA United States
- Employees
- ACTU N/A
- IGA N/A
- Industry
- ACTU
- IGA Investment Managers
- Sector
- ACTU
- IGA Finance
- Exchange
- ACTU NYSE
- IGA Nasdaq
- Market Cap
- ACTU 135.0M
- IGA 149.1M
- IPO Year
- ACTU 2024
- IGA N/A
- Fundamental
- Price
- ACTU $11.90
- IGA $10.12
- Analyst Decision
- ACTU Strong Buy
- IGA
- Analyst Count
- ACTU 1
- IGA 0
- Target Price
- ACTU $20.00
- IGA N/A
- AVG Volume (30 Days)
- ACTU 68.4K
- IGA 42.3K
- Earning Date
- ACTU 05-15-2025
- IGA 01-01-0001
- Dividend Yield
- ACTU N/A
- IGA 8.93%
- EPS Growth
- ACTU N/A
- IGA N/A
- EPS
- ACTU N/A
- IGA N/A
- Revenue
- ACTU N/A
- IGA N/A
- Revenue This Year
- ACTU N/A
- IGA N/A
- Revenue Next Year
- ACTU N/A
- IGA N/A
- P/E Ratio
- ACTU N/A
- IGA N/A
- Revenue Growth
- ACTU N/A
- IGA N/A
- 52 Week Low
- ACTU $5.51
- IGA $7.77
- 52 Week High
- ACTU $11.99
- IGA $8.88
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- IGA 66.06
- Support Level
- ACTU N/A
- IGA $9.98
- Resistance Level
- ACTU N/A
- IGA $10.10
- Average True Range (ATR)
- ACTU 0.00
- IGA 0.10
- MACD
- ACTU 0.00
- IGA 0.01
- Stochastic Oscillator
- ACTU 0.00
- IGA 100.00
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategy.